Literature DB >> 6125200

A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing.

R S Hornung, B A Gould, H Kieso, E B Raftery.   

Abstract

1 The effect of once daily nadolol therapy in sixteen ambulant patients with essential hypertension has been closely assessed during exercise and over 24 h by continuous intra-arterial recording. 2 The drug was well tolerated and showed similar efficacy to other beta-adrenoceptor blocking agents. Whilst blood pressure reduction was observed throughout the whole day, it was not uniform and lost significance during the morning period when blood pressure levels were highest. 3 This provides further evidence that the antihypertensive action of a beta-adrenoceptor drug over 24 h cannot be predicted from its plasma half-life which, with regard to nadolol, is up to 24 h. 4 An explanation for the loss of blood pressure control during the morning may be that the rapid rise in blood pressure leading to the peak levels at this time may be mediated through alpha- rather than beta-adrenergic receptors at the periphery.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125200      PMCID: PMC1427580          DOI: 10.1111/j.1365-2125.1982.tb04938.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  The Oxford continuous blood-pressure recorder--technical and clinical evaluation.

Authors:  A D Goldberg; E B Raftery; H L Green
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

2.  Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

Authors:  R J Lee; D B Evans; S H Baky; R J Laffan
Journal:  Eur J Pharmacol       Date:  1975 Sep-Oct       Impact factor: 4.432

3.  Beta-blockers: once or three times a day?

Authors:  T Reybrouck; A Amery; R Fagard; P Jousten; P Lijnen; E Meulepas
Journal:  Br Med J       Date:  1978-05-27

4.  Static exercise in untreated systemic hypertension.

Authors:  D J Ewing; J B Irving; F Kerr; B J Kirby
Journal:  Br Heart J       Date:  1973-04

5.  New system for recording ambulatory blood pressure in man.

Authors:  M W Millar-Craig; D Hawes; J Whittington
Journal:  Med Biol Eng Comput       Date:  1978-11       Impact factor: 2.602

6.  Hybrid system for fast data reduction of long-term blood-pressure recordings.

Authors:  P M Cashman; F D Stott; M W Craig
Journal:  Med Biol Eng Comput       Date:  1979-09       Impact factor: 2.602

7.  The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased.

Authors:  M Wilson; G Morgan; T Morgan
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

8.  Effect of once-daily atenolol on ambulatory blood pressure.

Authors:  M W Craig; D Kenny; S Mann; V Balasubramanian; E B Raftery
Journal:  Br Med J       Date:  1979-01-27

9.  Initial treatment of the young hypertensive: thiazide diuretic or beta-adrenoreceptor-blocking agent in a single daily dose?

Authors:  R D Gordon
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

10.  Circadian variation of blood-pressure.

Authors:  M W Millar-Craig; C N Bishop; E B Raftery
Journal:  Lancet       Date:  1978-04-15       Impact factor: 79.321

View more
  3 in total

1.  The effects of oxprenolol on ambulatory intra-arterial blood pressure in essential hypertension.

Authors:  M W Millar-Craig; S Mann; V Bala Subramanian; D G Altman; E B Raftery
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 2.  Does anxiety or cardiovascular reactivity have a causal role in hypertension?

Authors:  R H Rosenman
Journal:  Integr Physiol Behav Sci       Date:  1991 Oct-Dec

Review 3.  Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial.

Authors:  Barry L Carter; Elizabeth A Chrischilles; Gary Rosenthal; Brian M Gryzlak; Eric L Eisenstein; Mark W Vander Weg
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-12-24       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.